Spark Therapeutics Profile

USD 1.08  1.94%

Sale by Katherine High of 100 shares of Spark Therapeutics

Spark Therapeutics insider trading alert for sale of common stock by Katherine High, President and Chief Scientific Officer, on September 17, 2018. This event was filed by Spark Therapeutics Inc with SEC on 2016-08-08. Statement of changes in beneficial ownership - SEC Form 4. Katherine High is currently serves as president chief scientific officer, director of Spark Therapeutics [view details]   

Spark Therapeutics Summary

Spark Therapeutics (ONCE) is traded on BATS Exchange in USA. It is located in PENNSYLVANIA U.S.A and employs 315 people. Spark Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 2.28 B. Spark Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. This company has 37.57 M outstanding shares of which 5.22 M shares are now shorted by private and institutional investors with about 10.13 trading days to cover. N/A currently holds about 647.23 M in cash with (15.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.23.
Check Spark Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Spark Therapeutics Target Price Odds Analysis

Odds Below 56.63HorizonTargetOdds Above 56.63
7.46%30 days 56.63 92.43%
Based on normal probability distribution, the odds of Spark Therapeutics to move above current price in 30 days from now is about 92.43% (This Spark Therapeutics probability density function shows the probability of Spark Therapeutics Stock to fall within a particular range of prices over 30 days) .

Spark Therapeutics Top Holders

Spark Therapeutics Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares5.5 M458.2 M
Wellington Management Group LlpCommon Shares3.5 M293 M
View Spark Therapeutics Diagnostics

Spark Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Spark Therapeutics Key Fundamentals

Spark Therapeutics Against Markets

Spark Therapeutics Current Ratings

Spark Therapeutics 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Spark Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Spark Therapeutics operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 315 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Spark Therapeutics SEC Filings
Spark Therapeutics SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameSpark Therapeutics
CEO, Co-Founder, DirectorJeffrey MarrazzoView All
Thematic Classification
Currently Active Investing Idea
Aggressive Defence
  Aggressive Defence
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
Business Address3737 Market Street
ExchangeBATS Exchange
CIK Number0001609351
Phone215 220 9300
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestJuly 31, 2018

Did you try this?

Run Portfolio Quick Import Now


Portfolio Quick Import

Import or update all your transactions via one easy-to-use interface
All  Next Launch Portfolio Quick Import

Spark Therapeutics Directors

Spark Therapeutics Corporate Directors

Robert Perez Director
Lars Ekman Independent Director
Lorris Betz Director
Additionally take a look at Your Equity Center. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.